Published in final edited form as:

Front Biosci (Landmark Ed). ; 18: 1311–1334.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

Andrew J. Cowan¹, George S. Laszlo², Elihu H. Estey^{2,3}, and Roland B. Walter^{2,3,4}

¹Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA

²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

³Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA

⁴Department of Epidemiology, University of Washington, Seattle, WA, USA

Abstract

Antibodies have created high expectations for effective yet tolerated therapeutics in acute myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation antigen found on AML blasts in most patients and, perhaps, leukemic stem cells in some. Treatment efforts have focused on conjugated antibodies, particularly gemtuzumab ozogamicin (GO), an anti-CD33 antibody carrying a toxic calicheamicin- γ_1 derivative that, after intracellular hydrolytic release, induces DNA strand breaks, apoptosis, and cell death. Serving as paradigm for this strategy, GO was the first anti-cancer immunoconjugate to obtain regulatory approval in the U.S. While efficacious as monotherapy in acute promyelocytic leukemia (APL), GO alone induces remissions in less than 25–35% of non-APL AML patients. However, emerging data from well controlled trials now indicate that GO improves survival for many non-APL AML patients, supporting the conclusion that CD33 is a clinically relevant target for some disease subsets. It is thus unfortunate that GO has become unavailable in many parts of the world, and the drug's usefulness should be reconsidered and selected patients granted access to this immunoconjugate.

Keywords

AML; Antibody; Calicheamicin; CD33; Gemtuzumab ozogamicin; Immunoconjugate; Review

2. INTRODUCTION

In 2012, approximately 13,780 individuals developed acute myeloid leukemia (AML) in the U.S. (1). Despite aggressive therapies, AML remains difficult to treat, and many patients will die as a consequence of treatment failure or complications from either treatment-related toxicities or impaired normal hematopoiesis. With contemporary 5-year relative survival

Send correspondence to: Roland B. Walter, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA, Tel: 206-667-3599, Fax: -206-667-6519, rwalter@fhcr.org. Andrew J. Cowan and George S. Laszlo have contributed equally to this work.

Note: This is an un-copyrighted author manuscript that has been accepted for publication in the *Frontiers in Bioscience*. Cite this article as it appears in the *Journal of Frontiers in Bioscience*. Full citation can be found by searching the *Frontiers in Bioscience* ([/authors/](http://authors.frontiersin.org) search) following publication and at PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed>) following indexing. This article may not be duplicated or reproduced, other than for personal use or within the rule of "Fair Use of Copyrighted Materials" (section 107, Title 17, U.S. Code) without permission of the copyright holder, the *Frontiers in Bioscience*. From the time of acceptance following peer review, the full final copy edited article of this manuscript will be made available at <http://www.bioscience.org>. The *Frontiers in Bioscience* disclaims any responsibility or liability for errors or omissions in this version of the un-copyrighted manuscript or in any version derived from it by the National Institutes of Health or other parties.

rates of ~55% for patients <45 years of age but only ~5% for those above age 65 (2–6), the need for effective yet better tolerated new therapies is germane, and in this regard, monoclonal antibodies have raised expectations of accomplishing this goal. In fact, AML has served as a paradigm for their therapeutic use because of well-defined cell surface antigens and easy tumor cell accessibility. Remarkably, although AML cells often express aberrant forms or abundances of surface antigens relative to normal blood cells, true leukemia-specific epitopes have yet to be identified. Still, the number of antigens explored for the treatment of AML is rapidly increasing. Thus far, the most exploited is CD33, most notably as target for the immunoconjugate, gemtuzumab ozogamicin (GO). Being the first anti-cancer antibody-drug conjugate to obtain regulatory approval in the U.S., GO has been pivotal for the concept of antibody-based toxin delivery in oncology. In this article, we provide an overview of the properties of CD33 that render it suitable for targeting with a toxin-loaded antibody. We review the preclinical development of GO as well as the principles of its mechanisms of action and cellular resistance. We also discuss the clinical experience with GO over the last decade and consider biomarkers that could allow the pre-selection of patients most likely to respond to this drug. Finally, while emerging data on the efficacy of GO support the validity of CD33 as target in AML, we highlight some of the limitations of this approach and describe how these might be overcome in the future.

3. CD33, THE TARGET ANTIGEN

3.1. Physiological properties of CD33

CD33 is a 67kD member of the sialic-acid-binding immunoglobulin-like lectins (Siglecs), a discrete subset of the immunoglobulin (Ig) superfamily molecules (7–10). The human CD33 (Siglec-3) gene, located on chromosome 19q13.3, encodes a single pass, type I transmembrane glycoprotein consisting of an amino-terminal V-set Ig-like domain that mediates sialic-acid recognition, a C2-set Ig-like domain, a transmembrane domain, and an intracellular domain (11–14) (Figure 1). It may be expressed as a homodimer in its physiological state (15). At least in myeloid cell lines – expression in primary cells has not been studied – a shorter isoform lacking exon 2, which encodes the V-set domain, has been identified, but it is unknown whether this splice isoform is expressed on the cell surface (16). The cytoplasmic tail contains 2 conserved tyrosine-based signaling motifs, comprising a membrane-proximal immunoreceptor tyrosine-based inhibitory motif (ITIM) at position 340 and a membrane-distal ITIM-like motif at position 358. Upon phosphorylation, likely by Src family kinases, these tyrosine motifs provide docking sites for the recruitment and activation of the Src homology-2 (SH2) domain-containing tyrosine phosphatases, SHP-1 and SHP-2 (15, 17, 18). While both SHP-1 and SHP-2 are recruited to Y340, Y358 primarily functions to recruit SHP-2. In turn, these tyrosine phosphatases may dephosphorylate CD33 as part of a potential negative feedback control of CD33 signaling (17, 18) or may dephosphorylate and negatively regulate nearby receptors (15). The SH2 domain-containing suppressor of cytokine signaling 3 (SOCS3) can compete with SHP-1/2 for binding to phosphorylated CD33, leading to recruitment of the ECS (Elongin B/C-Cul2/Cul5-SOCS-box protein) E3 ubiquitin ligase complex and concomitant accelerated proteosomal degradation of both CD33 and SOCS3 (19). Indeed, CD33 can become ubiquitylated on several lysine residues located in the cytoplasmic domain. CD33 mono-ubiquitylation or poly-ubiquitylation, which requires intact ITIMs and is enhanced by tyrosine phosphorylation, involves both the lysine cluster around amino acid residues 309–315 and the 352 residue, whereas the first 2 intracellular lysines (residues 283 and 288) contribute little, if at all, to overall ubiquitylation of CD33 (20). Besides SOCS3, the Cbl family of E3 ubiquitin ligases can also bind to CD33 in an ITIM-dependent manner, and ubiquitylation of CD33 by Cbl proteins has been demonstrated experimentally (20).

In addition to tyrosine phosphorylation, CD33 is also rapidly phosphorylated on serine residues as a consequence of protein kinase C activation, with S307 being the strongest putative phosphorylation site. It has been speculated that this may occur as a consequence of cytokine signaling and may regulate its sialic acid-dependent binding activity, but the biological significance of serine phosphorylation of CD33 has not been elucidated in detail (21). Equally little is known about downstream signaling events, although cross-linking of CD33 can induce tyrosine phosphorylation of the proto-oncogenes Cbl and Vav in normal monocytes (22). Likewise, several signaling intermediates (Cbl, Vav, Syk, CrkL, and Plc- γ 1) have been shown to form complexes with CD33, at least upon pharmacological tyrosine phosphorylation (22, 23), but the physiological significance of these interactions is unknown.

CD33 exhibits a high degree of sequence similarity with 9 other Siglecs that, together, encompass the rapidly evolving subset of “CD33-related Siglecs” (8). These are mainly expressed on leukocytes in a cell type-specific manner. In healthy individuals, CD33 is primarily found on multipotent myeloid precursors, unipotent colony-forming cells, and maturing granulocytes and monocytes but not outside the hematopoietic system; it is down-regulated to low levels on peripheral granulocytes and resident macrophages while it is retained on circulating monocytes as well as dendritic cells (24–28). Besides expression in the myeloid cell lineage, CD33 may be found on subsets of B lymphocytes and activated human T and natural killer cells (16, 29–34). *In vitro* studies of normal bone marrow indicated that CD33 is not expressed on pluripotent hematopoietic stem cells (26, 27, 35) (Figure 2). Consistently, clinical studies demonstrated delayed but durable multilineage engraftment after transplantation of CD33-depleted autografts in patients with AML (36, 37), providing further evidence that normal hematopoietic stem cells lack CD33. The putative promoter sequence of CD33 contains a critical PU.1 site (38) but the regulation of CD33 expression has so far not been studied in detail; nevertheless, down-regulation of CD33 has been observed on monocytes by activation via T-cell contact, Fc γ receptor cross-linking, or pharmacological stimulation with phorbol myristate acetate or lipopolysaccharide (39).

The physiological function of CD33 is poorly understood. Similar to other CD33-related Siglecs, sialic acid-dependent cell adhesion with preference for α 2-6 over α 2-3 sialyllactosamines has been demonstrated (13, 17, 40). The adhesive properties of CD33 are modulated by α 1-3 linked fucose (“fucosylation”), which reduces binding to α 2-3 sialyllactosamines (40), as well as by endogenous sialoglycoconjugates that are present on the cell surface as *cis* ligands (13). Intrinsically, CD33-mediated cell adhesion is regulated by the proximal ITIM motif (13, 17) as well as glycosylation of the extracellular domains; in fact, mutation of a single N-linked glycosylation site in the V-set Ig-like domain can unmask CD33’s ligand binding function (41). Because of the ITIM and ITIM-like motifs, CD33 is thought to function as an inhibitory receptor by reducing the activity of tyrosine kinase-driven signaling pathways (10). In support of this notion, early studies demonstrated that cross-linking of CD33 with CD64 (FCGR1A, the high-affinity Fc γ receptor 1a), limits CD64-mediated tyrosine phosphorylation and Ca⁺⁺ mobilization through SHP-1 (15, 18). Increasing evidence suggests that the primary function of CD33-related Siglecs may involve dampening of host immune responses and setting of appropriate activation thresholds for the regulation of cellular growth, survival, and the production of soluble mediators (9). Consistently, CD33 constitutively suppresses the production of several pro-inflammatory cytokines (IL-1 β , TNF- α , and IL-8) by human monocytes in a sialic-acid ligand-dependent and SOCS3-dependent manner (39). Conversely, reduction of cell surface CD33, or interruption of sialic acid binding, leads to activation of p38 mitogen-activated protein kinase (MAPK) and enhances cytokine secretion (39). Likewise, SOCS3 activity reduces CD33-mediated repression of cytokine signaling and enhances cytokine-induced cellular

proliferation (19). On the other hand, antibody-engagement of CD33, along with CD33 phosphorylation and recruitment of SHP-1, reduces the syntheses of pro-inflammatory cytokines (TNF- α , IL-6, IL-1 β) and chemokines (RANTES, MCP-1, IL-8), in macrophages *in vitro* (42).

While limited, emerging data suggest a role of CD33 in the pathophysiology of several human diseases. Specifically, CD33 expression was found to be significantly reduced on monocytes of patients with type 2 diabetes relative to healthy individuals while secretion of several cytokines (TNF- α , IL-8, IL-12p70) was increased; consistently, high glucose conditions *in vitro* decreased CD33 transcription and protein expression, whereas TNF- α secretion and SOCS3 expression were increased, suggesting a role of CD33 in the generation of the pro-inflammatory milieu characteristic of diabetes (43). Furthermore, although no genetic disorders have been associated so far with mutations in CD33, a single nucleotide polymorphism (SNP) within the CD33 gene (rs3865444) has been associated with the development of Alzheimer's disease (44–46).

3.2. CD33 expression and internalization in AML

Consistent with its physiological expression as myeloid differentiation antigen, 85–90% of adult and pediatric AML patients are considered to have CD33⁺ disease, defined as the presence of CD33 on greater than 20–25% of the leukemic blasts (25, 47). CD33 is not a highly abundant antigen: quantitative flow cytometry studies estimated that AML blasts display an average of $\sim 10^4$ (range: $1 \times 10^3 - 5 \times 10^4$) CD33 molecules per cell (28, 48), and expression is typically even lower in immature (e.g. CD34⁺/CD38⁻/CD123⁺) cell subsets (49). From a drug development perspective, an important aspect of CD33 is its internalization when engaged with antibodies (23, 50–56). Mechanistic studies indicate that endocytosis of CD33/antibody complexes is largely limited and determined by the intracellular domain of CD33, while the extracellular and transmembrane domains play a minor role (23, 56). Forced tyrosine phosphorylation enhances the uptake of anti-CD33 antibodies, as does depletion of SHP-1 and SHP-2, at least in some cell lines, consistent with a role of tyrosine phosphorylation as regulator of this process (23). Consistently, disruption of the ITIMs by point mutations prevents optimal internalization of antibody-bound CD33 (56) although some internalization of CD33 occurs in an ITIM-independent manner. Furthermore, ubiquitylation of CD33 decreases CD33 cell surface abundance and increases the rate of CD33 internalization (20). Importantly, compared to antigens such as the transferrin receptor, the internalization process of CD33 is relatively slow (56). Together, the low expression of CD33 and the slow internalization of CD33/antibody complexes leads to relatively limited CD33-mediated drug uptake per unit of time; consequently, for an anti-CD33 antibody-drug conjugate to be most successful, a highly potent toxin will be required.

3.3. CD33 as a potential AML stem cell-associated antigen

It has long been recognized that AML encompasses functionally diverse cells, and disease origination from a leukemic stem cell was first suspected many decades ago (57). Despite intense efforts, however, the cellular origin of AML remains unclear, with ongoing dispute as to whether these leukemias arise from transformed hematopoietic stem cells or emerge as a result of genetic events occurring in more mature progenitor cells (57–62). Regardless of this controversy, the impetus to pursue CD33 as therapeutic target emanated not from the fact that blasts of the vast majority of AML patients express CD33 but from the early notion that some AMLs may predominantly or entirely involve committed CD33⁺ myeloid precursors, suggesting that this antigen could serve to eradicate underlying malignant stem cells in such leukemias (58). Specifically, classic studies on X chromosome inactivation patterns showed clonal dominance in multiple cell lineages (granulocytes, monocytes, erythrocytes, platelets, and occasionally B lymphocytes) in some leukemias, reflecting

origination and expansion at the level of pluripotent CD33⁺ hematopoietic stem cells. In others, clonal dominance was limited to granulocytes and monocytes, suggesting that expansion of the malignant clone could occur at the committed CD33⁺ myeloid precursor cell stage (63, 64); an example for the latter may be acute promyelocytic leukemia (APL), as small studies indicate that this disease is mainly expressed in granulocytes/monocytes and predominantly involves CD33⁺ precursors (65). In these “mature” leukemias, it was hypothesized that CD33⁺ precursors would be predominantly or completely normal. To test this assumption, CD33⁺ cells were removed *in vitro* via CD33-directed complement-mediated lysis or fluorescence-activated cell sorting in a small number of patients with such leukemias and the remaining CD33⁺ cells were placed in long-term culture together with irradiated allogeneic stroma cells (66, 67). Over time, CD33⁺ precursors from some patients indeed generated colony-forming cells with X chromosome inactivation patterns consistent with predominantly non-clonal hematopoiesis (66, 67). These seminal observations provided the scientific basis for the development and clinical testing of CD33-targeted therapy as a stem cell-directed treatment in a subset of AMLs.

4. GEMTUZUMAB OZOGAMICIN (GO)

4.1. Rationale for use of antibody-drug conjugate to target CD33

Crosslinking of CD33 on AML cells *in vitro* can inhibit the proliferation of these cells and activate a process leading to apoptotic cell death (68, 69). First attempts to exploit CD33 for targeted AML therapy in the clinic were undertaken with an unconjugated murine anti-CD33 antibody (M195). Although saturation of CD33 binding sites was observed with doses around 5 mg/m², however, only some patients had transient decreases in peripheral blast counts at this or higher doses (50). Subsequent studies employed a humanized IgG₁ construct of M195, lintuzumab (HuM195; SGN-33), which had >8-fold higher binding avidity than the parent antibody and, unlike M195, demonstrated antibody-dependent cell-mediated cytotoxicity (51, 70). Limited studies pointed towards some activity in APL when used in combination with all-trans retinoic acid (ATRA) in patients in morphological complete remission (CR) (71). On the other hand, lintuzumab had very modest activity as a single agent in overt non-APL AML, with infrequent achievement of CR or partial remission (PR) only amongst patients with relatively low tumor burden even at supra-saturating antibody doses (12–36 mg/m² per day for 4 days x 2 courses) that fully blocked CD33 binding sites throughout a 4-week period (72, 73). Higher doses of lintuzumab (1.5–8 mg/kg/week for 5 weeks, followed by every other week treatment for those who experienced clinical benefit) appeared somewhat more efficacious when investigated in patients with CD33⁺ myeloid malignancies: among the 17 patients with AML, 7 had an objective response (4 morphologic CRs, 2 partial remissions (PRs), and 1 morphologic leukemia-free state) with a median duration of therapy of 25.1 (range, 4.1–57.1) weeks (74).

Two randomized trials have tested lintuzumab together with conventional chemotherapy. In the first, 191 patients with relapsed/refractory AML were randomly assigned to receive mitoxantrone, etoposide, and cytarabine with or without lintuzumab (12 mg/m²). Addition of lintuzumab was associated with an insignificantly higher overall response rate (ORR; CR + CR with incomplete platelet recovery [CRp]: 36% vs. 28%, *p*=0.28) but unchanged overall survival (OS) (75). In the second, 211 patients older than age 60 with untreated AML were randomized to receive low-dose cytarabine (20 mg subcutaneously twice daily for 10 days) with either lintuzumab (600 mg/week for 4 doses in cycle 1 and every other week for 2 doses in subsequent cycles) or placebo in a double-blinded phase 2b study. Again, addition of lintuzumab did not improve OS (76). Ultimately, because of these negative results, the clinical development of lintuzumab was terminated in 2010.

The lack of significant tumor reducing effects of saturating or supra-saturating doses of unconjugated anti-CD33 antibodies in patients with overt non-APL AML indicated that anti-CD33 antibodies would be useful for AML therapy only if they served as a carrier of another biologically active agent. The feasibility of such an approach was suggested by studies with radiolabeled anti-CD33 antibodies showing selective uptake of the radio-immunoconjugate by AML cells and rapid saturation of leukemic blast cells in peripheral blood and bone marrow at intravenous doses of 5mg/m^2 (50, 52, 77). While the endocytic property of CD33 proved to be a hurdle for the delivery of radioiodine due radio-immunoconjugate internalization and metabolism and, consequently, relatively short residence times in the marrow (50, 52, 77), it spurred efforts to develop CD33-targeting antibody-drug conjugates carrying a toxic payload.

4.2. Development of GO

The class of toxin selected were the calicheamicins, highly potent and reactive antitumor antibiotics of the enediynes family that were originally isolated from fermentations of the soil microorganism *Micromonospora echinospora* ssp. *calichensis* in a screen for potent DNA damaging agents (78–81). The parent compound, calicheamicin- γ_1^I , has been shown to interact with double-stranded DNA in the minor groove in a relatively sequence-specific manner *in vitro* (82). Following reduction by cellular thiols, the enediyne moiety undergoes rearrangement to form a 1,4-benzenoid diradical that abstracts hydrogens from the phosphodiester backbone of DNA, resulting in single- and double-strand lesions (82, 83) (Figure 3); the latter involve direct double-strand breaks and, as a major lesion, bistranded damage that consists of an abasic site on one strand and a direct strand break on the other (84). This DNA damage elicits a strong cellular response with cell cycle arrest in the G₂/M phase followed by either DNA repair or, if damage is overwhelming, apoptosis and cell death. While the response to the initial DNA damage remains incompletely understood, calicheamicin-induced double-strand breaks activate DNA repair through activation of ATM/ATR and DNA-dependent protein kinase (DNA-PK) (85, 86). In turn, ATM activation leads to activation of Chk1/2 and G₂/M cell cycle arrest (85, 87). DNA-PK phosphorylates H2AX in rapid response to DSBs, a step that is required for subsequent recruitment of DNA damage repair proteins (88). Consistently, cells defective in ATM or DNA-PK are hypersensitive to calicheamicins (83, 89), as are cells deficient in the ERCC2/XRD gene, which is involved in the nucleotide excision repair pathway (90), supporting the notion that the extent of DNA damage and damage repair is central for the toxic effects of calicheamicins. Some experimental studies have suggested that calicheamicin-induced cytotoxicity could involve non-apoptotic (i.e. necrotic) pathways, e.g. through activation of poly(ADP-ribose) polymerase 1 (PARP1) and exhaustion of NAD⁺ levels (91). However, the mitochondrial pathway of apoptosis appears to be predominantly utilized during calicheamicin-induced cell death, which may be triggered in a p53-independent and death receptor/FADD-independent manner via activation of mitochondrial permeability transition, cytochrome c release, involvement of pro-apoptotic Bcl-2 family proteins (e.g. Bax and Bak), and activation of caspases (92, 93). In line with this cytotoxic mechanism, microarray studies in yeast indicate that calicheamicin- γ_1^I alters the expression of genes involved in chromatin arrangement, DNA repair and/or oxidative damage, DNA synthesis and cell cycle checkpoint control but also a variety of metabolic, biosynthetic, and stress response genes, as well as ribosomal proteins (94).

Experiments with free and antibody-bound calicheamicin analogues determined the structure-activity profile of a series of these toxins (95). For conjugation via periodate oxidized carbohydrates contained on the anti-MUC1 antibody, CTM01, thiol hydrazide derivatives were prepared by displacement at the methyltrisulfide moiety of the parent analogues. This process results in a “carbohydrate conjugate” capable of releasing active

drug both by hydrolysis of the hydrazone bond at low pH as well as by reduction of the disulfide bond. Compared with calicheamicin- γ_1^I , analogues that were missing the rhamnose at the end of the DNA binding region were found ineffective as conjugates *in vivo*; in contrast, 2 analogues (calicheamicin- α_3^I and N-acetyl-calicheamicin- γ_1^I) in which the DNA binding region was intact yet the amino sugar was either eliminated or modified showed a clear therapeutic advantage over calicheamicin- γ_1^I . Addition of methyl groups as steric bulk adjacent to the disulfide in the linker resulted in enhanced anti-tumor activity and an improved therapeutic window, likely because of increased stability of the linker in the serum. Together, these early studies identified the N-acetyl-calicheamicin- γ_1^I dimethyl hydrazide derivative as having an optimal therapeutic window when conjugated to an antibody (95). Of note, although the potency of this hydrazide is 2–8 fold less than that of the corresponding parent compounds, it remains 100–1,000-fold more potent than clinically used anti-cancer agents. While not suited as free drug due to a narrow therapeutic window, this potency renders a calicheamicin a good candidate as toxin for antibody-based therapeutics (78).

During early development, a murine antibody (P67.6) recognizing the V-set Ig-like domain of CD33 (96) was conjugated to the N-acetyl-calicheamicin- γ_1^I dimethyl hydrazide derivative (“carbohydrate conjugate”) as well as to a N-acetyl-calicheamicin- γ_1^I dimethyl acid, N-hydroxysuccinimide ester; conjugation of the latter occurred via lysine residues of the antibody, resulting in an “amide conjugate” stable to hydrolysis (97). While inclusion of the hydrazone was not necessary for anti-tumor activity of the anti-MUC1 antibody (98), only the carbohydrate conjugate of P67.6 showed good potency and selectivity against CD33⁺ human AML cells *in vitro* and in xenograft models, demonstrating the importance of rapid release of the toxic moiety from its conjugated state under acidic conditions such as those in lysosomal vesicles for anti-AML activity (97). Subsequently, P67.6 was humanized by grafting complementarity-determining regions into a human IgG₄ kappa framework (hP67.6) to minimize immunogenicity, and then conjugated with the calicheamicin derivative via an acid-labile hybrid 4-(4'-acetylphenoxy)butanoic acid linker to yield GO (99) (Figure 4). Of note, hP67.6 contains an IgG₄ core-hinge mutation that protects the therapeutic from Fab-arm exchange with endogenous human IgG₄ and thereby provides stabilization of the drug (100). However, only about 50% of the antibody is linked to calicheamicin- γ_1^I moieties, with an average loading of 4–6 molecules of the calicheamicin- γ_1^I derivate per antibody, while the remaining antibody is unconjugated (101).

5. PRECLINICAL OBSERVATIONS WITH GO

Initial preclinical studies showed that GO exerted selective cytotoxicity against CD33⁺ AML cells, effectively inhibiting colony-forming cells in pediatric and adult AML specimens *in vitro* whereas a control immunoconjugate did not, and caused regression of CD33⁺ AML cell line xenografts in athymic mice (99). Subsequent *in vitro* studies have confirmed these findings and provided insight into the cellular characteristics that are relevant for the clinical GO efficacy (Table 1).

In contrast to other anti-CD33 antibodies (68, 69), both P67.6 and hP67.6 are largely non-toxic against CD33⁺ AML cell lines and human AML specimens (87, 97, 102). It is thus thought that the antibody component primarily functions as a carrier to facilitate cellular uptake of the calicheamicin- γ_1^I derivative into CD33⁺ cells (Figure 5). The contribution of non-receptor mediated endocytic drug uptake, a possibility suggested by limited *in vitro* studies with CD33⁺ acute lymphoblastic leukemia cell lines (103), for clinical GO efficacy is unknown. Internalized CD33/GO complexes are routed to lysosomes, where the toxic moiety is presumably released (54, 104). The free calicheamicin- γ_1^I derivative can then enter the nucleus and initiate DNA damage. This putative mechanism of action implies a

critical role for the intracellular accumulation of the calicheamicin- γ_1^I derivative as well as the cellular response to the toxin's DNA damaging effect for GO-induced cytotoxicity (Table 1). Conceptually, the intracellular load of activated calicheamicin- γ_1^I is impacted by the amount of GO uptake, the efficacy of toxin release from the antibody and subsequent activation via cellular thiols, as well as toxin inactivation/metabolism or expulsion. However, while induction of DNA damage appears to be a prerequisite for GO-induced cytotoxicity (105, 106), it is not sufficient, indicating that the toxicity of the calicheamicin- γ_1^I moiety is modulated by the cell's ability to repair DNA damage and the activity of downstream pro- and anti-apoptotic pathways. Overall, the sensitivity to the toxic moiety varies over 100,000-fold between individual primary AML cells samples (107), an observation that emphasizes the importance of patient-specific factors for the clinical efficacy of GO.

Several patient-specific factors have been identified: most importantly, studies have repeatedly shown that drug efflux mediated by members of the adenosine triphosphate (ATP) binding cassette (ABC) superfamily of proteins, predominantly P-glycoprotein (ABCB1) and to a lesser degree multidrug resistance protein 1 (MRP1; ABCC1) but not breast cancer resistance protein (BCRP; ABCG2), mediate resistance to GO; conversely, inhibition of drug efflux effectively increases GO-induced cytotoxicity *in vitro* (87, 108–113). Taken together, these investigations have identified drug efflux as a major determinant of GO's anti-AML activity. Experimental studies also revealed a striking, quantitative relationship between CD33 expression and GO efficacy in engineered human AML cell lines and demonstrated the requirement of GO/CD33 complex internalization for GO-induced cytotoxicity (56). Thus, the amount of GO uptake is a limiting factor for GO efficacy. In support of this notion, CD33 expression levels directly correlate with the *in vitro* sensitivity of immature AML cell fractions to GO (102, 114). While the role of DNA repair and downstream signaling pathways for GO efficacy has not yet been examined in detail, Bcl-2 family proteins modulate GO cytotoxicity against AML cell lines (110). Furthermore, recent studies found activated PI3K/AKT signaling to be associated with GO resistance *in vitro* in primary AML cells, whereas the investigational AKT inhibitor, MK-2206, sensitizes various human AML cells to GO or free calicheamicin- γ_1^I (106). Likewise, limited data suggest that MEK1/2 activity may be involved in resistance to GO (115). Curiously, the presence of an FLT3/ITD mutation has been associated with increased sensitivity of immature AML cells to GO (114) but, so far, studies have not identified this marker to predict clinical response to GO. Finally, some studies have suggested Syk expression to be a biomarker of response to GO, and depletion of Syk to result in unresponsiveness to GO (116). However, in our experience, depletion of Syk by lentivirus-mediated siRNA expression did not affect GO cytotoxicity in engineered AML cell lines (R.B.W. unpublished observation).

A number of studies have indicated that the sensitivity of AML cells to GO can be enhanced through the use of other agents. Such chemosensitizing effects have been observed with histone deacetylase inhibitors (117), DNA methyltransferase I inhibitors (116, 118), the farnesyl transferase inhibitor, tipifarnib (119), heat shock protein-90 inhibitors (40), anti-CD45 antibodies (120), as well as mitoxantrone (121). Furthermore, the combination of GO with other conventional chemotherapeutics such as cytarabine, daunorubicin, idarubicin, doxorubicin, etoposide, or 6-mercaptopurine has additive cytotoxic effects *in vitro*, whereas methotrexate and vincristine may antagonize the effects of GO (121, 122). Interestingly, no rigorous studies have attempted to define the optimal timing when GO should be given with other agents. The timing, especially with respect to the cell cycle status, is likely of some importance, however, in view of data from *in vitro* studies suggesting that resting cells are relatively less susceptible to GO while treatment with granulocyte colony-stimulating factor (G-CSF) sensitizes to GO (103, 123). Finally, an interesting yet unstudied aspect of CD33-

targeted immunotherapy is the question whether shorter isoforms lacking the extracellular V-set Ig-like domain and antibody epitope (16) could modulate the efficacy of anti-CD33 antibody-based drugs.

6. CLINICAL PHARMACOLOGY OF GO

Pharmacokinetic studies in rats and monkeys identified the hepatobiliary system as the major excretion pathway for single and repeated doses of GO (101). *In vitro*, numerous metabolites of GO are formed, with biotransformation pathways involving both liver microsomes (oxygenation and demethylation) and the cytosol (acetylation of calicheamicin- γ_1^I derivative) (101). In humans, most of the available information on pharmacokinetics and pharmacodynamics is from adult patients who received 1–2 doses of GO at 9 mg/m² given 14–28 days apart on the phase 2 monotherapy trials. A mean maximum plasma concentration of 2.86 ± 1.35 mg/L was measured shortly after the end of the first 2-hour infusion of GO, and near complete saturation of CD33 antigenic sites in the peripheral blood was reached within 3–6 hours (55, 124). The drug elimination half-life proved highly variable, ranging from 72.4 ± 42.0 hours to 45.1 ± 25.2 hours for hP67.6 and calicheamicin, respectively, after the first dose of GO (124). Even 2 weeks after drug administration, circulating levels of GO are sufficient to partially saturate CD33 sites in the peripheral blood (55). Consistently, the area under the curve (AUC) was found to be higher in the second dosing period, with a 94% increase relative to the first administration (239 ± 196 vs. 123 ± 105 mg $\times$ h/L) and a corresponding decrease in clearance (0.132 ± 0.153 vs. 0.265 ± 0.229 L/h), perhaps related to the decreased peripheral blood CD33 antigen load at the time of second dosing; the latter would imply that CD33 antigen binding impacts pharmacokinetics as the principal means of elimination of hP67.6 from the plasma. After the second dose of GO, maximum serum concentrations were higher (3.67 ± 1.30 mg/L) and drug elimination longer (half-lives of 93.7 ± 67.4 hours and 61.1 ± 45.4 hours for hP67.6 and calicheamicin- γ_1^I , respectively) than after the first dose. The nearly parallel time-concentration plasma curves for hP67.6 and total calicheamicin- γ_1^I in most patients suggested that the toxic moiety remained largely bound to the antibody; indeed, free calicheamicin- γ_1^I could only be measured for a relatively short time following the end of drug infusion (124). Of note, although inter-patient variability is high, the fundamental pharmacokinetics do not appear to differ in relationship to age, gender, or ethnicity (124–127), and, among a set of 59 patients, no relationship was found between the pharmacokinetic parameters and response (124).

7. CLINICAL EFFICACY OF GO

7.1. Early clinical studies and accelerated approval of GO

A phase 1 study among 40 adults with relapsed/refractory CD33⁺ AML who received up to 3 doses of GO in 2-week intervals found morphologic elimination of leukemia in 8 (20%) patients, with 3 (7.5%) achieving CR and 2 (5%) achieving CRp. As dose-limiting non-hematologic toxicity was not reached, the highest dose level of 9 mg/m², which provided almost complete saturation of CD33 binding sites, was chosen for further study (128). Three open-label, multicenter single-arm phase 2 trials then evaluated GO in a larger cohort of adults with CD33⁺ *de novo* AML in first relapse. An interim analysis on 142 patients (median age: 61 [range: 22–84] years) who typically received 2 doses of GO 14 days apart showed an ORR of 29.6% (CR: 16.2%; CRp: 13.4%) (129). Presented with these results, the Oncology Drugs Advisory Committee (ODAC) concluded at the March 14, 2000 meeting that this drug provided a useful therapeutic option in patients >60 years of age with CD33⁺ AML in first relapse who would not be candidates for standard cytotoxic chemotherapy (101). The U.S. Food and Drug Administration (FDA) accepted this recommendation, and GO was given accelerated marketing approval on May 17, 2000 for this indication. Of note, the approval regulations not only required the sponsor to complete the original phase 2

studies in relapsed AML but also mandated the conduct of randomized, controlled trials to confirm the clinical benefit of GO when added to conventional chemotherapy in patients with *de novo* AML (101).

7.2. Subsequent clinical trials and discontinuation of commercial availability of GO

The final report of the 3 pivotal phase 2 trials on 277 patients confirmed the early results in relapsed AML, with 35 (12.6%) and 36 (13.0%) patients achieving CR and CRp, respectively, for an ORR of 25.6%, although remission durations were relatively short (130). Numerous studies have subsequently investigated GO in various clinical situations. As results from most of these trials have been reviewed previously in detail (131–137), we will only highlight those trials that are most informative regarding the potential clinical utility of GO.

7.2.1. Treatment of APL—GO is likely most effective in APL. For example, single agent GO resulted in molecular CR in 9 of 11 patients with molecularly relapsed APL tested after 2 doses and in 13 of 13 patients tested after the 3rd dose (138). Additional case reports corroborate the notion of very high efficacy of GO in the setting of minimal residual disease in APL, including patients with very advanced disease (139, 140). Furthermore, phase 2 trials suggest that GO can substitute for anthracycline therapy even in high-risk disease, and add benefit to therapy with ATRA (141, 142).

7.2.2. Treatment of pediatric non-APL AML—So far, only a few clinical studies have explored GO in childhood AML, primarily in patients with relapsed/refractory disease, and GO has no established role in this patient population. However, a large randomized trial testing the addition of GO to induction chemotherapy was led by the Children's Oncology Group (AAML0531) and has recently completed accrual of >1,000 participants but preliminary outcome results are expected for 2013 at the earliest.

7.2.3. Treatment of adult non-APL AML—Several phase 2 studies investigated GO monotherapy in unselected patients with newly diagnosed and/or relapsed/refractory non-APL AML. While these studies confirmed single agent activity of GO, the ORRs have typically not exceeded 25–35% and were occasionally quite disappointing, particularly in heavily pretreated patients. Of note, most of these studies followed a 2-weekly schedule of GO administration. Less well explored is the use of GO given at shorter intervals. However, the ALFA group has relatively recently reported the use of GO in fractionated, lower doses (3 mg/m² on days 1, 4, and 7) with promising efficacy and acceptable toxicity (143–145), but no direct, controlled comparisons with the traditional administration schedule have been made.

A wealth of studies have explored GO with other therapeutics or chemosensitizers and overall yielded mixed results. As most were small, single arm trials, no firm conclusions can be drawn from the majority of these studies as to the efficacy of GO relative to other drugs, or whether the addition of GO provided any benefit over what would have been achieved with the other therapeutics alone. Recently, however, several well controlled large studies have been conducted that congruently show that GO improves survival in a significant and relatively well defined subset of patients with newly diagnosed non-APL AML when added to conventional chemotherapy (58) (Table 2). In the MRC/NCRI AML15 trial, 1,113 predominantly adult patients were randomized to receive a single dose of GO (3 mg/m²) on day 1 of the first of two induction courses with one of three induction regimens (cytarabine/daunorubicin/etoposide, daunorubicin/cytarabine, fludarabine/cytarabine/G-CSF/idarubicin). While adding GO did not affect ORRs or survival across the entire study cohort, subgroup analyses showed that addition of GO improved OS at 5 years in patients with favorable

cytogenetics (79% vs. 51%; $p=0.0003$) but not in those with unfavorable cytogenetics (8% vs. 11%; $p=0.4$). There was also a survival benefit for some intermediate-risk patients, as indicated by an internally validated index using cytogenetics, age, and performance status, which predicted that ~70% of these patients had an improved 5-year OS if given GO (146).

In the ALFA 0701 trial, 278 patients with primary AML aged 50–70 years received daunorubicin/cytarabine with or without GO (3 mg/m²) on days 1, 4, and 7; a second course of daunorubicin/cytarabine was given for residual disease on day 15. Patients in remission then received 2 courses of daunorubicin/cytarabine with or without GO (3 mg/m²) on day 1 of each cycle. While there was no statistically significant difference in ORRs and treatment-related mortality (TRM) between the 2 arms, the event-free survival (EFS) at 2 years was significantly superior in the GO arm (40.8% vs. 17.1%, $p=0.0003$), as was disease-free survival (DFS) (50.3% vs. 22.7%, $p=0.0003$) and OS (53.2% vs. 41.9%, $p=0.037$). Subgroup analysis showed that the EFS benefit occurred in patients with favorable/intermediate cytogenetics but not in those with an adverse karyotype (145). In the GOELAMS AML 2006 IR study, adults aged 18–60 years with *de novo* AML and intermediate karyotype received daunorubicin/cytarabine with or without GO (6 mg/m²) on day 4; GO was also added to consolidation therapy according to the initial randomization (147). Among 238 analyzed patients, there was no difference in ORRs or TRM between the 2 treatment arms. Overall, there was also no statistically significant difference in EFS (GO vs. control: 51% vs. 33%) or OS (53% vs. 46%) at 3 years. However, subgroup analyses showed that in patients who did not undergo allogeneic hematopoietic cell transplantation (HCT), EFS was significantly higher in the GO group (53.7% vs. 27%, $p=0.0308$). Finally, in the MRC/NCRI AML16 trial, 1,115 adults aged 51–84 years with AML or high-risk myelodysplastic syndromes (MDS; >10% marrow blasts) received either daunorubicin/cytarabine or daunorubicin/clofarabine for 2 cycles with or without GO (3 mg/m²) on day 1 of the first induction course (148). Similar to the other trials, there was no significant difference in ORRs and TRM between the treatment arms, although the patients receiving GO had a slightly lower likelihood of persistent disease (17% vs. 21%, $p=0.06$). However, use of GO was associated with reduced relapse risk (at 3 years: 68% vs. 76%; $p=0.007$) and superior DFS (21% vs. 16%; $p=0.04$) as well as OS (25% vs. 20%; $p=0.05$). A meta-analysis of AML15 and AML16 on 2,224 patients showed a significant benefit of GO for risk of relapse (odds ratio [OR]: 0.82 [95% confidence interval: 0.72–0.93], $p=0.002$) and survival (OR: 0.88 [0.79–0.98], $p=0.02$); the survival benefit was seen in patients with favorable-risk (OR: 0.47 [0.28–0.77]) and intermediate-risk (OR: 0.84 [0.73–0.97]) but not adverse-risk (OR: 1.02 [0.81–1.27]) disease (148).

The results from these European studies differ from the SWOG trial S0106, which was developed with the drug sponsor to fulfill the post-approval commitment to the FDA. Six hundred thirty-seven patients aged 18–60 years with *de novo* AML were accrued to receive up to 2 cycles of induction chemotherapy with daunorubicin/cytarabine with or without a single dose of GO (6 mg/m²) on day 4 of the first induction (149). Unlike the European studies in which identical doses of conventional chemotherapeutics were used in both arms, S0106 used a lower daunorubicin dose with GO (45 mg/m² vs. 60 mg/m²). Overall, among the 596 evaluable patients, S0106 showed no difference in response or survival in either induction or post-consolidation with the addition of GO, but a trend towards improved OS was seen in patients with favorable-risk leukemias (hazard ratio: 0.49 [0.12–2.04], although S0106 was not powered to detect important outcome differences in this patient subset. As there was an attempt to achieve equi-toxicity with the lower dose of daunorubicin in the GO arm, the S0106 trial is confounded by the lower dose of daunorubicin administered to patients receiving GO, which might mask a greater benefit of the immunoconjugate. Nonetheless, based on the lack of pre-specified overall improvement in outcome, S0106 was prematurely terminated (150).

In contrast to its use in induction therapy, so far no study has documented a benefit of GO when used in consolidation. ECOG used a high-dose cytarabine-containing post-remission strategy incorporating a single dose of GO (6 mg/m²) for patients 17–60 years of age in first CR in a randomized phase 3 trial. Among 352 randomized patients, results of intent-to-treat analyses failed to provide any evidence of a benefit of GO in this trial (151). In the HOVON-43 study, 232 patients 60 years or older who achieved a first CR after intensive induction chemotherapy were randomized to 3 cycles of GO (6 mg/m² every 4 weeks) or no post-remission therapy; again, no differences in relapse probability, survival, or non-relapse mortality were noted (152).

7.2.4. Treatment of the elderly or unfit with non-APL AML—In contrast to the situation when GO is added to intensive chemotherapy, its benefit when combined with low-dose chemotherapy is perhaps more limited. This is suggested by a recent trial conducted by the MRC/NCRI, in which 495 patients were randomized to receive low-dose cytarabine with or without GO at 5 mg/m² on day 1 of every course; in this study, GO almost doubled the CR rate (30% vs. 17%, $p=0.006$) but did not improve the 12-month overall survival (153).

7.2.5. Withdrawal of GO from commercial market—Following discussions with the FDA, Pfizer voluntarily withdrew the new drug application for GO in the U.S. in 2010 as a result of the outcome of S0106, specifically the lack of overall survival benefit in the entire study cohort and the increased rate of early mortality in the GO arm (154). GO was withdrawn from the U.S. and European markets, but continues to be commercially available in Japan, where it has received full regulatory approval (155).

8. BIOMARKERS OF GO'S CLINICAL EFFICACY

The biomarker that has thus far been most recognized as predictor of GO's clinical efficacy with regard to improvement of survival is, as discussed in the previous section in detail, the cytogenetic/molecular profile of the leukemia. In addition, emerging data suggest that CD33 SNPs may prove useful as biomarkers for long-term benefit of GO as well. A number of other AML cell-associated factors – including drug efflux activity, CD33 expression levels, CD33 saturation, circulating CD33 antigenic load, and perhaps methylation status of SOCS3 – have been described as predictors of short-term response, i.e. reduction in tumor cell loads and/or achievement of CR, but it is unclear whether they could also serve as predictors of long-term benefit. Moreover, it has not been studied to what degree these factors underlie the observed relationship between disease risk and GO efficacy.

Consistent with preclinical studies indicating the central role of drug efflux for GO-induced cytotoxicity, correlative studies on biospecimens from patients enrolled in GO monotherapy trials showed an association between P-glycoprotein as well as MRP1 activity with persistence of marrow blasts, failure to achieve CR, or reduced *in vitro* drug-induced apoptosis (143, 156). This susceptibility to drug efflux may significantly limit the efficacy of GO in clinical practice, especially for the treatment of relapsed or refractory non-APL AML. It is well established that ABC transporter activity, in particular mediated by P-glycoprotein, predicts for therapeutic failure of standard induction therapy (157); thus, the same factor that predicts for failure of conventional chemotherapy and need for salvage therapy also predicts for failure of GO. Additionally, increasing evidence links ABC drug transporters to protection of cancer stem cells – the intended targets for GO – from chemotherapeutic agents (158). In contrast to drug efflux, the effect of CD33 expression on GO efficacy was initially uncertain, and several smaller studies did not find a correlation between CD33 expression levels and response to GO (103, 122). However, later correlative studies conducted on specimens from patients enrolled on the phase 2 trials with GO monotherapy found higher CD33 expression levels on AML blasts to be associated with favorable

outcome after GO monotherapy, although multivariate analyses suggested that drug efflux was the more relevant factor for clinical GO resistance than CD33 expression levels (159). A conceivable explanation for this difficulty to demonstrate a quantitative relationship between CD33 expression and clinical efficacy of GO could include the recent observation that CD33 expression levels are inversely associated with favorable cytogenetic/molecular disease features (160) or the possibility that CD33 abundance on disease-relevant stem/progenitor subsets of AML cells may not be adequately reflected by the average CD33 expression of bulk blasts. In line with the former notion, older data, again derived from pediatric AML, indicated that AML patients with high CD33 expression on AML blasts have worse outcomes than those with low CD33 expression when treated with conventional chemotherapy (161). Undoubtedly, this relationship between CD33 expression and inherent AML disease biology could modify the association between CD33 expression and GO efficacy and render such correlative studies challenging. To make matters more complex, recent data raised the possibility that some CD33 SNPs may not only be associated with CD33 expression levels but also response to GO-containing chemotherapy (162). Specifically, homozygosity for the variant allele (TT) at the coding SNP, rs12459419 (C>T; A14V), homozygosity of the reference allele (AA) at the coding SNP, rs2455069 (A>G; R69G), and the 3' UTR SNP, rs1803254 (G>C) have been associated with significantly lower CD33 expression on AML blasts as compared to other genotypes. Moreover, among Caucasians, homozygosity (GG) at the coding SNP, rs35112940 (G>A; R304G), was independently associated with improved relapse-free survival relative to the other genotypes in a cohort of pediatric patients treated with GO-containing multi-agent chemotherapy (AAML03P1) but not in a cohort of pediatric patients treated with multi-agent chemotherapy that did not contain GO (St. Jude AML02 trial) (163). Whether these SNPs directly influence the function of CD33 and response to GO is currently under active investigation.

Considering the relationship between GO uptake and efficacy, it is not surprising that *in vitro* studies have linked reduced CD33 saturation to reduced GO-induced cytotoxicity (103). While the clinically used doses of GO are typically saturating, a high CD33-antigenic load in the peripheral blood probably can act as antibody sink and lead to reduced CD33 saturation in the marrow, thereby adversely affecting GO efficacy (103). An important yet neglected aspect of CD33 uptake is the timing of GO administration. Early studies indicated that surface CD33 levels return to pretreatment levels within 72 hours after anti-CD33 antibody administration despite internalization and modulation (55, 70). This observation suggests that repeated administrations of lower, (near-)saturating doses of GO every 3 days, as clinically pioneered by the ALFA group (143–145), may enhance intracellular accumulation of the calicheamicin- γ_1^I derivative over the initial biweekly administration schedule.

Finally, preliminary data suggest that the methylation status of SOCS3 may serve as biomarker of responsiveness to GO. Specifically, in an uncontrolled, retrospective study on 24 patients treated with GO alone or in combination with chemotherapy at a single institution, methylation of the SOCS3 CpG island was found in 8; there was a statistically insignificant increase in response rate (86% vs. 56%; $P=0.17$) and longer overall survival (25.1 vs. 10.3 months; $P=0.09$) in patients with SOCS3 hypermethylation (164).

9. CLINICAL TOXICITIES OF GO

At 9 mg/m², GO commonly causes acute infusional reactions, with ~30% and 10% of patients experiencing grade 3/4 infusion-related events after the first and second dose, respectively. In the registration trials, such toxicities included chills (8%), fever (6%), hypotension (4%), nausea (3%), and hypertension (2%). Of note, hypotension – typically

transient and fluid responsive – could occur several hours after completion of drug administration (130). Corticosteroids are effective in reducing these reactions (165). Subsequent other common grade 3/4 toxicities include invariable myelosuppression (neutropenia [98%], thrombocytopenia [99%]), transient and reversible liver enzyme abnormalities (hyperbilirubinemia [29%], elevation in aspartate aminotransferase [18%] or alanine aminotransferase [9%]), sepsis (17%), fever (13%), chills (9%), nausea/emesis (10%), pneumonia (8%), dyspnea (8%), hypertension (8%), hypotension (8%), asthenia (6%), and neutropenic fever (6%) (130). As a curious rare side effect possibly related to effective elimination of CD163⁺ macrophages/monocytes, isolated cases with severe toxic symptoms during intravascular hemolysis secondary to impaired hemoglobin scavenging have been reported in children (166).

A characteristic adverse event that was noticed from the beginning of clinical drug testing is sinusoidal obstruction syndrome (SOS) or veno-occlusive disease (VOD) (129, 130, 167). GO-associated SOS presents as tender hepatomegaly, portal hypertension, fluid retention, weight gain as well as ascites and encephalopathy at later stages, with ascites being pathognomonic for the disease (168). Developing a median of 10–14 days following GO treatment, SOS is more likely when the drug is given at doses higher than 6 mg/m² or when it is combined with a hepatotoxic agent (e.g. thioguanin); in the initial clinical studies, SOS was observed most commonly when GO was used pre-transplant, in particular – in up to 65–90% in small patient series – when patients underwent allogeneic HCT within 3–4 months of receiving GO (169, 170). A small study suggested the possibility that the risk of SOS might be modified by a SNP within the glutathione-S-transferase genes, but this link is currently not firmly established (53). The identification of several GO-associated SOS cases shortly after drug approval led the FDA to request the establishment of an industry-sponsored prospective observational registry. Experience from this registry suggested a rate of SOS of around 10% (14.9% and 8.2% in patients undergoing or not undergoing HCT, respectively) (170). SOS proved highly fatal: among 99 cases captured in the FDA's adverse drug event reporting system, 80% required hospitalization and 66% ultimately died (170). Treatment options for GO-associated SOS are poorly defined but limited data indicate that defibrotide may have a role in either prophylaxis or treatment of this condition (120, 171, 172). The etiology of SOS remains somewhat elusive although, based not only on clinical but also histological findings, toxic effects on cells in hepatic sinusoids are likely underlying this pathologic process. Proposed mechanisms include exposure to unconjugated calicheamicin- γ_1^I in the circulation, nonspecific uptake of GO by CD33⁺ Kupffer cells, or CD33-mediated uptake of GO by one or more of the cell populations in the liver (173); indeed, some data suggest that perhaps, CD33 is also found on hepatocytes (174).

Not surprisingly, data from trials in which GO has been used at lower doses indicate that dose is the key element contributing to GO toxicity. In fact, in most of the recent phase 3 trials, there were no major differences with regard to non-hematologic toxicities between the GO-containing and the control arm when GO was added to conventional induction chemotherapy. Specifically, in the MRC/NCRI AML15 and AML16 trials, hematologic recovery was identical in both arms although patients treated with GO required more platelet transfusions and more days of intravenous antibiotics (146, 148). In contrast, in the ALFA trial, prolonged recovery of neutrophil and platelet counts were observed in the GO arm (145), possibly as a reflection of the more intense, fractionated dosing rather than single administration of GO. SOS was observed very infrequently but remained highly fatal, with 2 out of 3 affected patients dying as a consequence of this toxicity (145).

10. CONCLUSION

Emerging data from large, well-controlled trials indicate that GO benefits many but not all patients with AML, supporting the conclusion that CD33 is a valid target for some disease subsets. Therefore, the current unavailability of GO in many parts of the world is unfortunate, a fact that has led to repeated calls from leading AML experts to both manufacturer and regulatory authorities to reconsider the drug's value and grant selected patients access to this antibody-drug conjugate (58, 175–178).

The long-term benefit of GO in APL and other favorable-risk leukemias, and possibly some leukemias with less favorable prognoses, would be consistent with an ablative effect on CD33⁺ leukemic stem or progenitor cells in these cases. In view of the available clonal analyses and clinical data with unconjugated anti-CD33 antibodies, this possibility is perhaps most suggested for APL, but high expression of CD33 and low drug efflux activity may partially explain its exquisite sensitivity toward GO. Remarkably, studies have yet to determine whether GO, besides “debulking” of mature CD33⁺ progeny, can directly kill CD33⁺ AML stem cells, and whether improved survival from GO is related to successful targeting of such cells (58), a concept that warrants further experimental investigations.

The clinical testing of GO has clearly demonstrated that CD33 is a challenging target for toxin-loaded antibodies: antigen expression at relatively low abundance, slow conjugate internalization, and ABC drug transporter activity limit intracellular toxin accumulation in AML cells and may account at least partly for this difficulty (58). Considering these limitations, rational strategies to improve CD33-targeted immunotherapy would include those that increase CD33 expression/turnover or inhibit drug efflux (179). Additionally, interference with pro-/anti-apoptotic signaling downstream of the toxin-inflicted cellular damage may lower the apoptotic threshold and increase cellular toxicity of GO. An alternative entails the development of novel immunoconjugates employing more potent toxins that are less prone to extrusion by ABC transporters, or anti-CD33 antibody-based therapeutics that utilize fundamentally different mechanisms of actions, e.g. engagement of the host's immune system for effective elimination of AML. While an antibody-drug conjugate that utilized a thiol-containing maytansine derivative recently failed in early clinical testing (180), other CD33-targeting agents have been developed and show promising preclinical activity (181–184).

Last but not least, the experience with GO is an important reminder of the pitfalls of taking a ‘one size fits all approach’ in drug development for AML, when often benefits are limited to certain groups of patients. As we learn to identify those AMLs likely to respond to certain agents such as CD33-directed antibody-drug conjugates, we may restrict trial eligibility to patients with these specific leukemias. As a consequence, greater emphasis will be placed on recruiting adequate numbers of patients for the testing of these drug, and our efforts either need to focus more on collaborative, international studies or, more likely, be willing to accept higher false positive and false negative rates or detection of only relatively large differences between treatment and controls (185). With any luck, the lessons learned with GO will help to shift the drug approval process away from dependence on results seen in all AML patients towards the recognition that this disease, like many others, is intrinsically heterogeneous and must be treated accordingly.

Acknowledgments

This work was supported by grants from the National Cancer Institute/National Institutes of Health (P30-CA015704-35S6, R21-CA155524), the Hope Foundation (SWOG Development Award), and the Alex's Lemonade Stand Foundation (‘A’ Award).

Abbreviations

ALFA	Acute Leukemia French Association
AML	acute myeloid leukemia
APL	acute promyelocytic leukemia
DFS	disease-free survival
ECOG	Eastern Cooperative Oncology Group
ECS	Elongin B/C-Cul2/Cul5-SOCS-box protein
EFS	event-free survival
FDA	U.S. Food and Drug Administration
GO	gemtuzumab ozogamicin
GOELAMS	Groupe Oest-Est d'étude des Léucémies Aiguës et autres Maladies du Sang
HCT	hematopoietic cell transplantation
HOVON	Dutch-Belgian Cooperative Trial Group for Hematology-Oncology
ITIM	immunoreceptor tyrosine-based inhibitory motif
MRC/NCRI	Medical Research Council/National Cancer Research Institute
ORR	overall response rate
OS	overall survival
Siglec	sialic-acid-binding immunoglobulin-like lectin
SH2	Src homology-2
SHP-1/2	SH2 domain containing phosphatase-1/2
SNP	single nucleotide polymorphism
SOCS3	suppressor of cytokine signaling 3
SOS	sinusoidal obstruction syndrome
SWOG	Southwest Oncology Group
U.S	United States
TRM	treatment-related mortality
VOD	veno-occlusive disease

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* 2012; 62(1):10–29. [PubMed: 22237781]
2. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *N Engl J Med.* 1999; 341(14): 1051–1062. [PubMed: 10502596]
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. *Blood.* 2005; 106(4):1154–1163. [PubMed: 15870183]
4. Estey E, Döhner H. Acute myeloid leukaemia. *Lancet.* 2006; 368(9550):1894–1907. [PubMed: 17126723]
5. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra

- J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*. 2010; 115(3):453–474. [PubMed: 19880497]
6. Howlader, N.; Noone, AM.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Altekruse, SF.; Kosary, CL.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Eisner, MP.; Lewis, DR.; Chen, HS.; Feuer, EJ.; Cronin, KA.; Edwards, BK. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute; Bethesda, MD: 2011. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site
 7. Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. *Glycobiology*. 2006; 16(1):1R–27R. [PubMed: 16118287]
 8. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol*. 2007; 7(4):255–266. [PubMed: 17380156]
 9. Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? *Immunology*. 2011; 132(1):18–26. [PubMed: 21070233]
 10. Crocker PR, McMillan SJ, Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. *Ann N Y Acad Sci*. 2012; 1253:102–111. [PubMed: 22352893]
 11. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. *Blood*. 1988; 72(1):314–321. [PubMed: 3390608]
 12. Simmons D, Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. *J Immunol*. 1988; 141(8):2797–2800. [PubMed: 3139766]
 13. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. *Blood*. 1995; 85(8):2005–2012. [PubMed: 7718872]
 14. Yousef GM, Ordon MH, Foussias G, Diamandis EP. Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. *Gene*. 2002; 286(2):259–270. [PubMed: 11943481]
 15. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. *Blood*. 2000; 96(2):483–490. [PubMed: 10887109]
 16. Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB, Quintanilla-Cecconi AM, García-Alonso A, Alvarez-López DMR, García-Peñarubia P. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. *J Leukoc Biol*. 2006; 79(1):46–58. [PubMed: 16380601]
 17. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. *J Biol Chem*. 1999; 274(17):11505–11512. [PubMed: 10206955]
 18. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. *Eur J Immunol*. 1999; 29(11):3440–3449. [PubMed: 10556798]
 19. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. *Blood*. 2007; 109(3):1061–1068. [PubMed: 17008544]
 20. Walter RB, Häusermann P, Raden BW, Teckchandani AM, Kamikura DM, Bernstein ID, Cooper JA. Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. *Traffic*. 2008; 9(2):267–279. [PubMed: 18062779]
 21. Grobe K, Powell LD. Role of protein kinase C in the phosphorylation of CD33 (Siglec-3) and its effect on lectin activity. *Blood*. 2002; 99(9):3188–3196. [PubMed: 11964282]
 22. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. *Leuk Res*. 2001; 25(12):1115–1125. [PubMed: 11684286]
 23. Walter RB, Raden BW, Zeng R, Häusermann P, Bernstein ID, Cooper JA. ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. *J Leukoc Biol*. 2008; 83(1):200–211. [PubMed: 17947393]

24. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. *Blood*. 1983; 62(1):124–132. [PubMed: 6190518]
25. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. *Leuk Res*. 1984; 8(4):521–534. [PubMed: 6590930]
26. Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. *Blood*. 1986; 68(5):1030–1035. [PubMed: 3768529]
27. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. *J Exp Med*. 1989; 169(5):1721–1731. [PubMed: 2469766]
28. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. *Leukemia*. 1989; 3(5):339–348. [PubMed: 2716349]
29. Handgretinger R, Schafer HJ, Baur F, Frank D, Ottenlinger C, Buhring HJ, Niethammer D. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells. *Immunol Lett*. 1993; 37(2–3):223–228. [PubMed: 7505004]
30. Nakamura Y, Noma M, Kidokoro M, Kobayashi N, Takei M, Kurashima S, Mukaiyama T, Kato S. Expression of CD33 antigen on normal human activated T lymphocytes. *Blood*. 1994; 83(5):1442–1443. [PubMed: 8118046]
31. Schmidt-Wolf IG, Grimm B, Lefterova P, Johnston V, Scheffold C, Huhn D, Serke S. Propagation of large numbers of cells of a human mixed-lineage T-lymphoid/myeloid. *Br J Haematol*. 1995; 90(3):512–517. [PubMed: 7646987]
32. Márquez C, Trigueros C, Franco JM, Ramiro AR, Carrasco YR, López-Botet M, Toribio ML. Identification of a common developmental pathway for thymic natural killer cells and dendritic cells. *Blood*. 1998; 91(8):2760–2771. [PubMed: 9531586]
33. Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. *Blood*. 1998; 92(9):3203–3209. [PubMed: 9787156]
34. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, Yavuz S, Karsli F, Yurdakul S, Yazici H, Akoglu T. Phenotypic characteristics of B cells in Behcet's disease: increased activity in B cell subsets. *J Rheumatol*. 1999; 26(4):826–832. [PubMed: 10229403]
35. La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish *in vitro* hematopoiesis in long-term marrow cultures. *Exp Hematol*. 1992; 20(4):442–448. [PubMed: 1373688]
36. Bernstein, ID.; Andrews, RG.; Berenson, R.; Bensinger, W.; Singer, JW.; Buckner, CD. Isolation of human hematopoietic stem cells. In: Champlin, RE.; Gale, RP., editors. *New Strategies in Bone Marrow Transplantation*. Wiley-Liss; New York: 1991.
37. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. *Blood*. 1992; 79(9):2229–2236. [PubMed: 1571539]
38. Bodger MP, Hart DN. Molecular cloning and functional analysis of the CD33 promoter. *Br J Haematol*. 1998; 102(4):986–995. [PubMed: 9734649]
39. Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. *Eur J Immunol*. 2005; 35(1):243–251. [PubMed: 15597323]
40. Brinkman-Van der Linden ECM, Varki A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. *J Biol Chem*. 2000; 275(12):8625–8632. [PubMed: 10722702]

41. Sgroi D, Nocks A, Stamenkovic I. A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. *J Biol Chem.* 1996; 271:18803–18809. [PubMed: 8702538]
42. Sutherland MSK, Lewis TS, Yu C, McEarchern JA, Drachman JG, Sievers EL, Grewal IS, Law CL. SGN-33 modulates cytokine and chemokine production by activated monocytes and macrophages [abstract]. *Blood.* 2006; 108(11):564a.
43. Gonzalez Y, Herrera MT, Soldevila G, Garcia-Garcia L, Fabian G, Pérez-Armendariz EM, Bobadilla K, Guzmán-Beltrán S, Sada E, Torres M. High glucose concentrations induce TNF- α production through the down-regulation of CD33 in primary human monocytes. *BMC Immunol.* 2012; 13:19. [PubMed: 22500980]
44. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rutherford E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Bretele MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet.* 2011; 43(5):429–435. [PubMed: 21460840]
45. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33

- and EPHA1 are associated with late-onset *alzheimer's* disease. *Nat Genet.* 2011; 43(5):436–441. [PubMed: 21460841]
46. Deng YL, Liu LH, Wang Y, Tang HD, Ren RJ, Xu W, Ma JF, Wang LL, Zhuang JP, Wang G, Chen SD. The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease. *Hum Genet.* 2012; 131(7):1245–1249. [PubMed: 22382309]
 47. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. *Blood.* 1986; 67(4):1048–1053. [PubMed: 2937468]
 48. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Differences in CD33 intensity between various myeloid neoplasms. *Am J Clin Pathol.* 2002; 118(4):560–566. [PubMed: 12375643]
 49. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Scherthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Expression of the target receptor CD33 in CD34+/CD38–/CD123+ AML stem cells. *Eur J Clin Invest.* 2007; 37(1):73–82. [PubMed: 17181570]
 50. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. *J Clin Oncol.* 1991; 9(3):478–490. [PubMed: 1999719]
 51. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. *Cancer Res.* 1992; 52(24):6761–6767. [PubMed: 1458463]
 52. van der Jagt RHC, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, Bernstein ID. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. *Cancer Res.* 1992; 52(1):89–94. [PubMed: 1530769]
 53. Audran R, Drenou B, Wittke F, Gaudin A, Lesimple T, Toujas L. Internalization of human macrophage surface antigens induced by monoclonal antibodies. *J Immunol Methods.* 1995; 188(1):147–154. [PubMed: 8551032]
 54. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L, Shochat D, Bernstein ID. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. *Cancer Res.* 1996; 56(9):2123–2129. [PubMed: 8616860]
 55. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger AS, van Dogen JJM. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: *in vivo* and *in vitro* saturation and internalization by leukemic and normal myeloid cells. *Blood.* 2001; 97(10):3197–3204. [PubMed: 11342449]
 56. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. *Blood.* 2005; 105(3):1295–1302. [PubMed: 15454492]
 57. Dick JE. Stem cell concepts renew cancer research. *Blood.* 2008; 112(13):4793–4807. [PubMed: 19064739]
 58. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. *Blood.* 2012; 119(26):6198–6208. [PubMed: 22286199]
 59. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. *Oncogene.* 2011; 30(9):1009–1019. [PubMed: 21076471]
 60. Lane SW, Gilliland DG. Leukemia stem cells. *Semin Cancer Biol.* 2010; 20(2):71–76. [PubMed: 20026405]
 61. Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. *Clin Cancer Res.* 2007; 13(12):3439–3442. [PubMed: 17575205]
 62. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? *Proc Natl Acad Sci U S A.* 2003; 100(Suppl 1):11842–11849. [PubMed: 14504387]
 63. Fialkow PJ, Singer JW, Adamson JW, Vaidya K, Dow LW, Ochs J, Moohr JW. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. *Blood.* 1981; 57(6):1068–1073. [PubMed: 6939452]

64. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. *N Engl J Med*. 1987; 317(8):468–473. [PubMed: 3614291]
65. Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? *Leukemia*. 2004; 18(3):375–384. [PubMed: 14737069]
66. Bernstein ID, Singer JW, Andrews RG, Keating A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G, Raskind W, et al. Treatment of acute myeloid leukemia cells *in vitro* with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. *J Clin Invest*. 1987; 79(4):1153–1159. [PubMed: 3470307]
67. Bernstein ID, Singer JW, Smith FO, Andrews RG, Flowers DA, Petersens J, Steinmann L, Najfeld V, Savage D, Fruchtman S, et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. *Blood*. 1992; 79(7):1811–1816. [PubMed: 1373089]
68. Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, Bacigalupo A, Moretta L, Mingari MC. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. *Proc Natl Acad Sci U S A*. 1999; 96(26):15091–15096. [PubMed: 10611343]
69. Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. *Proc Natl Acad Sci U S A*. 2001; 98(10):5764–5769. [PubMed: 11320212]
70. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. *Blood*. 1994; 83(7):1760–1768. [PubMed: 8142644]
71. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. *Clin Cancer Res*. 2000; 6(2):372–380. [PubMed: 10690513]
72. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. *Clin Cancer Res*. 1998; 4(6):1421–1428. [PubMed: 9626458]
73. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. *Leukemia*. 2003; 17(2):314–318. [PubMed: 12592328]
74. Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. *Leuk Lymphoma*. 2009; 50(8):1336–1344. [PubMed: 19557623]
75. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. *J Clin Oncol*. 2005; 23(18):4110–4116. [PubMed: 15961759]
76. Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized, phase IIb study of low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. *Haematologica*. 2013; 98(1):119–128. [PubMed: 22801961]
77. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. *Transplantation*. 1992; 54(5):829–833. [PubMed: 1440849]
78. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. *Curr Opin Pharmacol*. 2003; 3(4):386–390. [PubMed: 12901947]

79. Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB. Calicheimicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calicheimicin .gamma.II. J Am Chem Soc. 1987; 109(11):3464–3466.
80. Lee MD, Dunne TS, Chang CC, Ellestad GA, Siegel MM, Morton GO, McGahren WJ, Borders DB. Calicheimicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calicheimicin .gamma.II. J Am Chem Soc. 1987; 109(11):3466–3468.
81. Maiese WM, Lechevalier MP, Lechevalier HA, Korshalla J, Kuck N, Fantini A, Wildey MJ, Thomas J, Greenstein M. Calicheamicins, a novel family of antitumor antibiotics. taxonomy, fermentation and biological properties. J Antibiot (Tokyo). 1989; 42(4):558–563. [PubMed: 2722671]
82. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988; 240(4856):1198–1201. [PubMed: 3240341]
83. Elmroth K, Nygren J, Mårtensson S, Ismail IH, Hammarsten O. Cleavage of cellular DNA by calicheamicin gamma I. DNA Repair (Amst). 2003; 2(4):363–374. [PubMed: 12606118]
84. Dedon PC, Salzberg AA, Xu J. Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry. 1993; 32(14):3617–3622. [PubMed: 8466904]
85. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin *in vitro*: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003; 101(11):4589–4597. [PubMed: 12576328]
86. Mårtensson S, Nygren J, Osheroff N, Hammarsten O. Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiat Res. 2003; 160(3):291–301. [PubMed: 12926987]
87. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytotoxic effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000; 14(8):1436–1443. [PubMed: 10942240]
88. Yuan J, Adamski R, Chen J. Focus on histone variant H2AX: to be or not to be. FEBS Lett. 2010; 584(17):3717–3724. [PubMed: 20493860]
89. Sullivan N, Lyne L. Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin gamma II. Mutat Res. 1990; 245(3):171–175. [PubMed: 1700294]
90. van Duijn-Goedhart A, Zdzienicka MZ, Sankaranarayanan K, van Buul PP. Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin. Mutat Res. 2000; 471(1–2):95–105. [PubMed: 11080665]
91. Zhao B, Konno S, Wu JM, Oronsky AL. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by calicheamicin gamma I in human HL-60 cells. Cancer Lett. 1990; 50(2):141–147. [PubMed: 2109651]
92. Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, Dorken B, Wieder T, Daniel PT. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene. 2003; 22(57):9107–9120. [PubMed: 14647446]
93. Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol. 2009; 37(6):755–766. [PubMed: 19463775]
94. Watanabe CMH, Supekova L, Schultz PG. Transcriptional effects of the potent enediyne anti-cancer agent calicheamicin γ_1^I . Chem Biol. 2002; 9(2):245–251. [PubMed: 11880039]
95. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslakis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993; 53(14):3336–3342. [PubMed: 8324745]
96. Pérez-Oliva AB, Martínez-Esparza M, Vicente-Fernández JJ, Corral-San Miguel R, García-Peñarrubia P, Hernández-Caselles T. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology. 2011; 21(6):757–770. [PubMed: 21278227]

97. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslakis J, Flowers DA, Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. *Bioconjug Chem.* 2002; 13(1):40–46. [PubMed: 11792177]
98. Hamann PR, Hinman LM, Beyer CF, Greenberger LM, Lin C, Lindh D, Menendez AT, Wallace R, Durr FE, Upeslakis J. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. *Bioconjug Chem.* 2005; 16(2):346–353. [PubMed: 15769088]
99. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslakis J, Shochat D, Mountain A, Flowers DA, Bernstein I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. *Bioconjug Chem.* 2002; 13(1):47–58. [PubMed: 11792178]
100. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 *in vivo*. *Nat Biotechnol.* 2009; 27(8):767–771. [PubMed: 19620983]
101. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. *Clin Cancer Res.* 2001; 7(6):1490–1496. [PubMed: 11410481]
102. Walter RB, Fairchild SE, Flowers DA, Hong TC, Bernstein ID. Priming with myeloid growth factors enhances CD33 expression, decreases P-glycoprotein activity, and improves efficacy of gemtuzumab ozogamicin against acute myeloid leukemia (AML) colony forming cells (CFC) [abstract]. *Blood.* 2008; 112:912a–913a. [PubMed: 18650465]
103. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. *Leukemia.* 2004; 18(2):316–325. [PubMed: 14614514]
104. McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA. Immunotoxin resistance in multidrug resistant cells. *Cancer Res.* 2003; 63(1):72–79. [PubMed: 12517780]
105. Yamauchi T, Matsuda Y, Tasaki T, Negoro E, Ikegaya S, Takagi K, Yoshida A, Urasaki Y, Ueda T. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells. *Cancer Sci.* 2012; 103(9):1722–1729. [PubMed: 22632031]
106. Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB. AKT signaling as a novel factor associated with *in vitro* resistance of human AML to gemtuzumab ozogamicin. *PLoS One.* 2013; 8(1):e53518. [PubMed: 23320091]
107. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hahlen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJ. Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. *Leukemia.* 2008; 22(12):2284–2285. [PubMed: 18563175]
108. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi K, Ohno R. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. *Leukemia.* 2002; 16(5):813–819. [PubMed: 11986941]
109. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. *Blood.* 2003; 102(4):1466–1473. [PubMed: 12689934]
110. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. *Blood.* 2004; 103(11):4276–4284. [PubMed: 14962898]
111. Walter RB, Raden BW, Thompson J, Flowers DA, Kiem HP, Bernstein ID, Linenberger ML. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells. *Leukemia.* 2004; 18(11):1914–1917. [PubMed: 15385942]
112. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia

and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. *Blood*. 2005; 106(10):3584–3593. [PubMed: 16051742]

113. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, Marie JP. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). *BMC Cancer*. 2008; 8:51. [PubMed: 18271955]
114. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. Analysis of factors that affect *in vitro* chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. *Leukemia*. 2010; 24(1):74–80. [PubMed: 19776761]
115. Matsumoto T, Jimi S, Hara S, Takamatsu Y, Suzumiya J, Tamura K. Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. *Leuk Lymphoma*. 2012; 53(7):1399–1405. [PubMed: 22242821]
116. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. *Leukemia*. 2006; 20(12):2093–2101. [PubMed: 17051243]
117. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. *Leukemia*. 2007; 21(2):248–252. [PubMed: 17122863]
118. Kurimoto M, Matsuoka H, Hanaoka N, Uneda S, Murayama T, Sonoki T, Nakakuma H. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. *Leukemia*. 2013; 27(1):233–235. [PubMed: 22814292]
119. Jawad M, Yu N, Seedhouse C, Tandon K, Russell NH, Pallis M. Targeting of CD34+CD38– cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia. *BMC Cancer*. 2012; 12:431. [PubMed: 23013471]
120. Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. *Blood*. 2008; 111(9):4813–4816. [PubMed: 18326813]
121. Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, Miyawaki S, Mano H, Furukawa Y. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis *in vitro*. *Anticancer Res*. 2009; 29(11):4589–4596. [PubMed: 20032408]
122. Morris KL, Adams JA, Liu JA. Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells *in vitro*, as a single agent and combined with other cytotoxic cells. *Br J Haematol*. 2006; 135(4):509–512. [PubMed: 17054677]
123. Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, Sutherland J, Nesterova A, Gerber HP, Sievers EL, Grewal IS, Law CL. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. *MAbs*. 2009; 1(5):481–490. [PubMed: 20065652]
124. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. *J Clin Pharmacol*. 2001; 41(11):1206–1214. [PubMed: 11697753]
125. Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. *Pharmacotherapy*. 2001; 21(10):1175–1180. [PubMed: 11601662]
126. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. *J Clin Pharmacol*. 2004; 44(8):873–880. [PubMed: 15286091]
127. Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshida F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. *Int J Hematol*. 2009; 89(4):460–469. [PubMed: 19360457]

128. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. *Blood*. 1999; 93(11):3678–3684. [PubMed: 10339474]
129. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. *J Clin Oncol*. 2001; 19(13):3244–3254. [PubMed: 11432892]
130. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJM, Bernstein ID, Appelbaum FR. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. *Cancer*. 2005; 104(7):1442–1452. [PubMed: 16116598]
131. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. *Cancer*. 2003; 98(10):2095–2104. [PubMed: 14601078]
132. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. *Drugs*. 2005; 65(16):2405–2427. [PubMed: 16266206]
133. Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. *Br J Haematol*. 2006; 132(4):398–409. [PubMed: 16412015]
134. Abutalib SA, Tallman MS. Monoclonal antibodies for the treatment of acute myeloid leukemia. *Curr Pharm Biotechnol*. 2006; 7(5):343–369. [PubMed: 17076651]
135. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. *Oncogene*. 2007; 26(25):3679–3690. [PubMed: 17530021]
136. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. *Cancer Treat Rev*. 2008; 34(1):49–60. [PubMed: 17942233]
137. Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. *Expert Opin Biol Ther*. 2011; 11(2):225–234. [PubMed: 21142804]
138. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. *Blood*. 2004; 104(7):1995–1999. [PubMed: 15187030]
139. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S, Meloni G, Tafuri A, Mandelli F, Lo Coco F. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). *Br J Haematol*. 2001; 115(1):63–65. [PubMed: 11722411]
140. Breccia M, Cimino G, Diverio D, Gentilini F, Mandelli F, Lo Coco F. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. *Haematologica*. 2007; 92(9):1273–1274. [PubMed: 17768126]
141. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH, Cortes JE, Kantarjian HM. Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. *Blood*. 2002; 99(11):4222–4224. [PubMed: 12010830]
142. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. *J Clin Oncol*. 2009; 27(4):504–510. [PubMed: 19075265]
143. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, Chevret S, Dombret H, Castaigne S. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. *Leukemia*. 2007; 21(1):66–71. [PubMed: 17051246]

144. Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association. *Am J Hematol.* 2012; 87(1):62–65. [PubMed: 22072535]
145. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet.* 2012; 379(9825):1508–1516. [PubMed: 22482940]
146. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JAL, Hunter A, Goldstone AH, Wheatley K. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. *J Clin Oncol.* 2011; 29(4):369–377. [PubMed: 21172891]
147. Delaunay J, Recher C, Pigneux A, Witz F, Vey N, Blanchet O, Lefebvre P, Luquet I, Guillerme I, Volteau C, Gyan E, Lioure B, Jourdan E, Bouscary D, Guieze R, Randriamalala E, Ojeda Uribe ME, Dreyfus F, Lacombe C, Béné MC, Cahn JY, Harousseau JL, Ifrah N. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract #79]. *Blood.* 2011; 118(21):37–38. [PubMed: 21518924]
148. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. *J Clin Oncol.* 2012; 30(32):3924–3931. [PubMed: 22851554]
149. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract #790]. *Blood.* 2009; 114(22):326–327.
150. SWOG. [Accessed on: December 26, 2012] 2010. <http://www.swogstat.org/ROS/ROSBooks/Spring2010/Leukemia.pdf>
151. Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood.* 2011; 117(20):5306–5313. [PubMed: 21415269]
152. Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. *Blood.* 2010; 115(13):2586–2591. [PubMed: 20103782]
153. Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. *Leukemia.* 2013; 27(1):75–81. [PubMed: 22964882]
154. Pfizer Inc; 2010. http://media.pfizer.com/files/products/mylotarg_hcp_letter.pdf [Accessed on: December 26, 2012.]
155. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. *Clin Cancer Res.* 2011; 17(20):6417–6427. [PubMed: 22003069]

156. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, Bernstein ID. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. *Blood*. 2001; 98(4):988–994. [PubMed: 11493443]
157. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? *Leukemia*. 2007; 21(6):1172–1176. [PubMed: 17429427]
158. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer*. 2005; 5(4): 275–284. [PubMed: 15803154]
159. Walter RB, Gooley TA, van der Velden VH, Loken MR, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. *Blood*. 2007; 109(10):4168–4170. [PubMed: 17227830]
160. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. *Blood*. 2012; 119(16):3705–3711. [PubMed: 22378848]
161. Dinndorf PA, Buckley JD, Nesbit ME, Lampkin BC, Piomelli S, Feig SA, Kersey JH, Hammond GD, Bernstein ID. Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. *Med Pediatr Oncol*. 1992; 20(3):192–200. [PubMed: 1574028]
162. Lamba J, Mortland LJ, Mitra A, Walter RB, Pollard JA, Alonzo TA, Gerbing RB, Hirsch BA, Raimondi SC, Franklin J, Meshinchi S. Clinical significance of CD33 non-synonymous single nucleotide polymorphisms (SNPs) in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin-containing chemotherapy [abstract]. *Blood*. 2011; 118(21):1489.
163. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK. Clinical significance of CD33 non-synonymous single nucleotide polymorphisms (SNPs) in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin-containing chemotherapy. *Clin Cancer Res*. 2013 in press.
164. Middeldorf I, Galm O, Osieka R, Jost E, Herman JG, Wilop S. Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). *Am J Hematol*. 2010; 85(7):477–481. [PubMed: 20575043]
165. Giles FJ, Cortes JE, Halliburton TA, Mallard SJ, Estey EH, Waddelow TA, Lim JT. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. *Ann Pharmacother*. 2003; 37(9):1182–1185. [PubMed: 12921496]
166. Maniecki MB, Hasle H, Friis-Hansen L, Lausen B, Nielsen OJ, Bendix K, Moestrup SK, Moller HJ. Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. *Blood*. 2008; 112(4):1510–1514. [PubMed: 18550848]
167. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. *Cancer*. 2001; 92(2):406–413. [PubMed: 11466696]
168. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). *Clin Lymphoma*. 2002; 2(Suppl 1):S35–39. [PubMed: 11970769]
169. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. *Blood*. 2003; 102(5):1578–1582. [PubMed: 12738663]
170. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. *Leuk Res*. 2007; 31(5):599–604. [PubMed: 16959316]

171. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. *Blood*. 2004; 103(5):1968. [PubMed: 14976063]
172. Lannoy D, Decaudin B, Grozieux de Laguerenne A, Barrier F, Pignon JM, Wetterwald M, Odou P. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. *J Clin Pharm Ther*. 2006; 31(4):389–392. [PubMed: 16882110]
173. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. *Blood*. 2002; 99(7):2310–2314. [PubMed: 11895761]
174. Maniecki MB, Hasle H, Bendix K, Moller HJ. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? *Leuk Res*. 2011; 35(6):e84–86. [PubMed: 21329979]
175. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin? *Lancet*. 2012; 379(9825):1468–1469. [PubMed: 22482941]
176. Foran JM. Gemtuzumab: time to bring back on the market? *Clin Adv Hematol Oncol*. 2012; 10(5):326–327. [PubMed: 22706544]
177. Neuberg DS. Reprise: gemtuzumab ozogamicin for older patients with acute myeloid leukemia. *J Clin Oncol*. 2012; 30(32):3905–3906. [PubMed: 22987082]
178. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM. Gemtuzumab ozogamicin: time to resurrect? *J Clin Oncol*. 2012; 30(32):3921–3923. [PubMed: 22987091]
179. Jager E, van der Velden VH, te Marvelde JG, Walter RB, Agur Z, Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. *PLoS One*. 2011; 6(9):e24265. [PubMed: 21915304]
180. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ, Marie JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. *Invest New Drugs*. 2012; 30(3):1121–1131. [PubMed: 21519855]
181. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmler M, Huls G, Fey G, Helfrich W. A novel AML-selective TRAIL fusion protein that is superior to gemtuzumab ozogamicin in terms of *in vitro* selectivity, activity and stability. *Leukemia*. 2009; 23(8):1389–1397. [PubMed: 19262596]
182. Sutherland, MSK.; Walter, RB.; Jeffrey, SC.; Burke, PJ.; Yu, C.; Harrington, KH.; Stone, I.; Ryan, MC.; Sussman, D.; Zeng, W.; Benjamin, DR.; Bernstein, I.; Senter, PD.; Drachman, JG.; McEarchern, JA. SGN-CD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML [abstract #3589]. 54th Annual Meeting of the American Society of Hematology; December 8–11, 2012; Atlanta, GA. 2012.
183. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW. T lymphocytes can be effectively recruited for *ex vivo* and *in vivo* lysis of AML blasts by a novel CD33/CD3-bispecific BiTE((R)) antibody construct. *Leukemia*. 2012 in press.
184. Heider, K-H.; Konopitzky, R.; Ostermann, E.; Lamche, H.; Küpcü, Z.; Kössl, C.; Adam, PJ.; Adolf, GR.; Borges, E. A novel Fc-engineered antibody to CD33 with enhanced ADCC activity for treatment of AML [abstract #1363]. 54th Annual Meeting of the American Society of Hematology; December 8–11, 2012; Atlanta, GA. 2012.
185. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood*. 2010; 116(14):2420–2428. [PubMed: 20538802]

Figure 1.

Structure of CD33. Scheme depicting the domain structure of CD33 as well as individual amino acids that have been implicated in phosphorylation or ubiquitylation events or have been identified as residues of relatively frequent non-synonymous single nucleotide polymorphisms (SNPs). Abbreviations: C2, C2-set Ig-like domain; P, phospho-; PKC, protein kinase C; SFKs, Src-family kinases; Ub, ubiquitin; V, V-set Ig-like domain.

Figure 2.

CD33 as myeloid differentiation antigen. Simplified hypothetical model of stem and progenitor cells in the human hematopoietic system, showing expression patterns of CD33 and CD34. This figure was initially published in *Blood* (58). Reproduced with permission from the American Society of Hematology.

Figure 3.

Calicheamicin-induced cytotoxicity. Scheme depicting the presumed mechanism of cytotoxicity of calicheamicins in AML cells. Abbreviations: BER, base excision repair; γ H2AX, phosphorylated H2AX; DSBs, double-strand breaks; HRR, homologous recombination repair; NER, nucleotide excision repair; NHEJ, non-homologous end joining; MMR, mismatch repair; SSBs, single-strand breaks

Figure 4. Schematic structure of GO. This figure was initially published in *Current Opinion in Pharmacology* (78). Reproduced with permission from Elsevier.

Figure 5. Schemes depicting the presumed mechanism of GO uptake, trafficking, and intracellular release of the calicheamicin- γ_1^I derivative with subsequent translocation into the nucleus or extrusion via ABC transporter proteins.

Table 1

Cellular parameters implicated in GO efficacy

Factor	Comment
Uptake of CD33/GO complexes	
<i>Receptor-mediated uptake</i>	
• CD33 expression levels	Quantitative relationship between CD33 expression and GO efficacy in engineered cell lines; expression levels associated with cytogenetic risk of AML and CD33 SNPs
• CD33 saturation	<i>In vitro</i> evidence linking reduced CD33 saturation to reduced GO cytotoxicity
• CD33 internalization	Relatively slow process, controlled by intracellular tyrosine motifs and likely tyrosine phosphorylation and ubiquitylation status of CD33
• Re-expression of CD33 binding sites	Surface CD33 levels return to pretreatment levels within 72 hours after CD33 antibody administration; could contribute to amount of internalized GO, in particular if given in fractionated doses.
<i>Non-receptor mediated uptake</i>	Suggested by experimental studies with CD33 ⁻ cell lines (clinical role unknown)
Intracellular trafficking of GO	Hypothetical
Activation of GO	Low pH in lysosomes required for release of calicheamicin- γ 1 ¹ moiety from antibody
Extrusion of GO	
• ABC family of drug transporters	Established role of P-glycoprotein and MRP1; role of other transporters unknown
Induction of cytotoxicity	
• Generation of SS- and DS-DNA breaks	Hypersensitivity of cell lines with defects in DNA repair to calicheamicins
• Mitochondrial pathways of apoptosis	Good experimental evidence for role of pro- and anti-apoptotic Bcl-2 protein family members
• Other downstream pro- or anti-apoptotic signaling pathways	Not examined in detail but MEK1/2 and AKT signaling may confer relative resistance
• Cell cycle status	Limited <i>in vitro</i> data suggesting that resting cells are relatively less susceptible to GO

Abbreviations: DS, double-stranded; GO, gemtuzumab ozogamicin; SNP, single-nucleotide polymorphism; SS, single-stranded Modified from a table that was initially published in *Blood* (58). Reproduced with permission from The American Society of Hematology

Table 2

Phase 3 studies of GO in newly diagnosed non-APL AML

Study	Reference	Disease	N	Age (median)	Treatment	Results
MRC/NCRI AML15	(146)	AML	1,113	0–71 (49)	± GO (3 mg/m ²) on day 1 of the first of two induction courses with either ADE, DA, or FLAG-IDA	No difference in ORR, TRM, relapse, or survival. Improved 5-year OS for favorable-risk subgroup (79% vs. 51%; p=0.0003) with GO; predicted 10% OS benefit for ~70% of patients with intermediate-risk disease
ALFA 0701	(145)	AML	278	59–66 (62)	± GO (3 mg/m ²) on days 1, 4, and 7 of DA induction and day 1 of each of 2 courses of DA consolidation	No difference in ORR or mortality. Improved 2-year EFS (40.8% vs. 17.1%; p=0.0003), DFS (50.3% vs. 22.7%, p=0.0003) and OS (53.2% vs. 41.9%, p=0.037) with GO. Survival benefit seen in favorable/intermediate- but not adverse-risk disease
GOELAMS AML 2006 IR	(147)	AML (intermediate risk)	238	18–60 (50)	± GO (6 mg/m ²) on day 1 with DA induction and MA consolidation	No difference in ORR, TRM, or 3-year EFS. Improved EFS with GO in patients who did not undergo allogeneic HCT (53.7% vs. 27%, p=0.0308)
MRC/NCRI AML16	(148)	AML, high-risk MDS	1,115	51–84 (67)	± GO (3 mg/m ²) on day 1 of the first of two induction courses with either DA or DCL ₀	No difference in TRM; trend towards reduced risk of persistent disease with GO (17% vs. 21%, p=0.06). Reduced 3-year relapse risk (68% vs. 76%; p=0.007) and superior DFS (21% vs. 16%; p=0.04) and OS (25% vs. 20%; p=0.05) with GO
SWOG S0106	(149, 150)	AML	596	18–60 (47)	± GO (6 mg/m ²) on day 4 of the first of up to two induction courses with DA *	Increased TRM in GO arm (5.7% vs. 1.4%; p=0.01). No difference in ORR, DFS, or OS. Possible trend towards improved OS in favorable-risk subgroup with GO (hazard ratio: 0.49 [0.12–2.04])

Abbreviations: ADE, cytarabine/daunorubicin/etoposide; DA, daunorubicin/cytarabine; DCL₀, daunorubicin/clofarabine; DFS, disease-free survival; FLAG-IDA, fludarabine/cytarabine/G-CSF/idarubicin; HCT, hematopoietic cell transplantation; MA, mitoxantrone/cytarabine; ORR, overall response rate (CR+CRi); OS, overall survival; TRM, treatment-related mortality.

* Daunorubicin was used at 60 mg/m²/day in the control (–GO) arm and 45 mg/m²/day in the GO arm. This table was initially published in *Blood* (58). Reproduced with permission from The American Society of Hematology.